Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07457736 · ClinicalTrials.gov registry record · Early Phase 1
Evaluation of [18F]GATT-44 for Positron Emission Tomography Imaging of the GABA Transporter-1
A Early Phase 1 study of Healthy Adult Participants, sponsored by Yale University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT07457736: Recruiting Early Phase 1 study of Healthy Adult Participants, sponsored by Yale University.
NCT07457736 is a Early Phase 1 study of Healthy Adult Participants that is actively recruiting participants, run by Yale University. The registered enrollment target is 32 participants, below the 72-participant average among 4 other Healthy Adult Participants trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07457736, a Early Phase 1 study of Healthy Adult Participants, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluate \[18F\]GATT-44 (aka \[18F\]GAT44), to characterize its pharmacokinetic, metabolic, and in vivo binding profile, and assess the reproducibility of kinetic and binding parameters. Assess specific binding levels of \[18F\]GATT-44 by conducting a test-block study in humans. Estimate human dosimetry of \[18F\]GATT-44 by performing whole-body imaging studies.
Primary Outcome
Regional TACs are analyzed with kinetic models to generate regional volume of distribution (VT), using the metabolite-corrected arterial plasma concentrations over time as input function. Standardized uptake values (SUV) may also be generated.
Conditions Studied
Interventions
- DRUG [ 18F]GATT-44
Study Locations (1)
Connecticut
- Yale University PET Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-03 |
| Est. Completion | 2030-01 |
| Phase | Early Phase 1 |
What NCT07457736 shows while recruiting
NCT07457736 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 72-participant average among 4 other Healthy Adult Participants trials with a reported enrollment target (56% lower).
The record links to 1 condition, with Healthy Adult Participants appearing as the primary indexed condition, and to 1 intervention - of which [ 18F]GATT-44 is the first listed.
NCT07457736 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT07457736 about?
NCT07457736 is a clinical study titled "Evaluation of [18F]GATT-44 for Positron Emission Tomography Imaging of the GABA Transporter-1". Evaluate \[18F\]GATT-44 (aka \[18F\]GAT44), to characterize its pharmacokinetic, metabolic, and in vivo binding profile, and assess the reproducibility of kinetic and binding parameters. Assess specific binding levels of \[18F\]GATT-44 by conducting a test-block study in humans. Estimate human dosim...
What is the current status of trial NCT07457736?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 32 participants. The study started on 2026-03. Estimated completion is 2030-01.
What conditions does trial NCT07457736 study?
This clinical trial studies the following conditions: Healthy Adult Participants.
What interventions are being tested in trial NCT07457736?
The interventions under investigation include: [ 18F]GATT-44 (DRUG).
Who is sponsoring clinical trial NCT07457736?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07457736 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Adult Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult Participants
RECRUITING · Phase 1
-
A Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, and Behavior in the Body of TBD11
RECRUITING · Phase 1
-
A Study to Learn if Itraconazole Changes How the Body Processes PF-07248144 (Study Medicine)
ACTIVE NOT RECRUITING · Phase 1
-
Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia